Heidi Just Raised $340M. The AI Scribe Is Becoming an Agentic Care Platform.

Heidi has raised US$100 million in Series C equity at a US$900 million valuation and secured another US$240 million in customer-acquisition financing from General Catalyst. The more important signal for healthcare administration is where the company is going next: beyond ambient documentation and toward AI agents that participate directly in care workflows.

This Is More Than a $100M Series C

Blackbird led Heidi's US$100 million Series C, with existing investors Phoenix Court, Point72 Private Investments and Headline participating. The equity financing values Heidi at US$900 million, or roughly A$1.26 billion.

Alongside the round, General Catalyst is providing US$240 million of customer-acquisition financing. Unlike traditional equity, that capital is earmarked for sales and marketing. Revenue generated from customers acquired through the facility is then used to repay General Catalyst with interest.

That structure matters. Heidi gets a large pool of growth capital without financing all of its customer acquisition through repeated equity dilution. CEO Tom Kelly told Forbes the commitment can support roughly four and a half years of growth investment.

Ambient Documentation Was the Wedge

Heidi built its initial adoption around a straightforward pain point: clinicians spending enormous amounts of time documenting encounters. Its free AI scribe created a low-friction entry point, while paid features and enterprise deployments expanded the commercial model.

The strategy appears to be working. Forbes reports annualised revenue reached $50 million in April, compared with approximately $1 million two years earlier. Kelly said roughly half of users remain on Heidi's free products while the other half have upgraded to premium capabilities.

Enterprise healthcare is also changing that mix. As hospitals and larger provider organizations formalize AI adoption, individual clinician usage increasingly converts into organization-level agreements.

The Next Product Is Not Another Scribe

Heidi has already expanded beyond documentation with longitudinal session linking, clinical evidence tools and clinician-patient communications. The next phase is more ambitious: direct care workflows powered by AI agents.

That mirrors a broader pattern RCAI is tracking across healthcare administration. Ambient documentation creates the data. The next generation of products uses that context to initiate and execute downstream work — follow-up communication, task management, clinical research, forms and eventually increasingly autonomous workflow execution.

The competitive question therefore shifts from who has the best scribe? to who owns enough workflow context to become the clinician's operating layer?

Why RCM Should Pay Attention

Heidi is not primarily an RCM company. But the progression is highly relevant to revenue-cycle leaders because documentation sits immediately upstream of coding, medical necessity, charge capture and reimbursement.

As ambient platforms move from transcription into agentic workflows, the boundary between clinical AI and administrative AI gets thinner:

• Documentation can become structured coding context.
• Clinical evidence can support medical-necessity workflows.
• Follow-up agents can trigger administrative tasks automatically.
• Longitudinal patient context can inform downstream revenue-cycle workflows.

The vendors that own the clinical encounter may have an increasingly valuable starting position for automating the administrative work generated by that encounter.

The Financing Model Is Also Worth Watching

General Catalyst's US$240 million facility is effectively a bet on Heidi's customer economics. The capital can only be deployed into customer acquisition, and repayment is tied to revenue generated from those acquired customers.

For a healthcare software company with strong retention and expanding enterprise adoption, that can create an unusual growth flywheel: external capital funds distribution, new customers generate recurring revenue, and equity can be preserved for product development and strategic expansion.

It also puts pressure on Heidi's core assumption — that customers acquired aggressively today remain valuable long after the acquisition financing has been repaid.

From $465M to $900M in Less Than a Year

Heidi's previous US$65 million Series B in 2025 valued the company at US$465 million. The new Series C nearly doubles that valuation while the company simultaneously scales into new markets, including France and Germany.

Kelly told Forbes that Heidi expects to reach cash-flow neutrality by the end of 2027 even while continuing its expansion.

The trajectory illustrates how quickly the ambient-AI category is evolving. The first phase was clinician adoption. The second was enterprise standardization. The third may be platform expansion into agentic care.

What to Watch

The key question is whether Heidi can translate its enormous documentation footprint into durable workflow ownership. Its scribe created distribution; enterprise agreements create monetization; agents could create substantially deeper integration.

If that happens, ambient AI may look less like a standalone software category and more like the front door into a much larger healthcare operating system.

That is why this financing matters beyond another healthcare AI unicorn. Heidi has enough capital, distribution and clinical context to test whether the winner in ambient documentation can become something considerably larger.